Animal and Cell Evaluation of Deep-Learning Lesion Detection Method
A new deep-learning pipeline for detecting lesions associated with the central vein sign (CVS) in brain imaging was evaluated across eight studies. It successfully identified 78 out of 111 reference lesions (70.3%) with an F1 score of 0.667 for one pathway and 0.706 for another, indicating comparative effectiveness.
- Tags
- #MSResearch
- Most relevant to
- —
- Human efficacy
- Not established from this source
- Mechanism
- Not reported
- Evidence strength
- Not graded
- Outcome
- Not reported
Why it matters
This approach could improve the efficiency of assessing lesions tied to multiple sclerosis, potentially reducing dependence on manual data interpretation.
What this does not prove
The results are based on a single-centre study with no validation in diverse clinical settings, suggesting the findings may be overly optimistic.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Not reported
- Participants / samples
- Not reported
- Randomised
- Not reported
- Controlled
- Not reported
- Primary endpoint met
- Not reported
- Relevant MS type
- Not reported
- Publication date
- 2026-09-28
- Evidence reviewed
- Abstract only
- Regulatory approval
- Not reported
- Research areas
- Not classified
- Biological target
- Not reported
- Pathway
- Not reported
- Population
- Not reported
- Size of effect
- Not reported
- Secondary endpoints
- Not reported
- MRI endpoints
- Not reported
- Biomarkers
- Not reported
- Safety
- Not reported
Original sources
- Primary evidenceA Central-Vein-Sign-Aware Deep-Learning Pipeline for Lesion Detection and Automated CVS Assessment on Brain SWIp: An Exploratory End-to-End Feasibility Study. ↗DOI: 10.3390/jimaging12100472
Supporting passages (9)
sample size basisA cohort of 64 clinical studies annotated by four readers was merged into a consolidated reference.
publication datePublication date: 2026-09-28
interventionTitle: A Central-Vein-Sign-Aware Deep-Learning Pipeline for Lesion Detection and Automated CVS Assessment on Brain SWIp: An Exploratory End-to-End Feasibility Study.
comparatorThe central vein sign (CVS) is a supportive imaging biomarker for multiple sclerosis (MS), but its manual assessment on susceptibility-weighted imaging with phase enhancement (SWIp) is time-consuming and reader-dependent.
primary endpointDetection is therefore the binding constraint, and a threshold sweep shows the associated overcounting of CVS-positive lesions is not separable from it by detector confidence alone.
follow upOn an eight-study evaluation, the pipeline recovered 78 of 111 reference lesions (70.3%); lesion-level F1 was 0.667 for Pathway A and 0.706 for Pathway B, rising to 0.785 and 0.818 when restricted to detected lesions, and a paired test found no significant difference between the pathways (p=1.00).
findingsOn an eight-study evaluation, the pipeline recovered 78 of 111 reference lesions (70.3%); lesion-level F1 was 0.667 for Pathway A and 0.706 for Pathway B, rising to 0.785 and 0.818 when restricted to detected lesions, and a paired test found no significant difference between the pathways (p=1.00).
limitationsAll operating thresholds were selected on these same eight studies, which were acquired on a single scanner, so the figures are single-centre development-set estimates rather than measures of clinical performance and are likely optimistic.
peer reviewedPublication types: Journal Article
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.